Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives

Table 2 Effect of cetuximab in phase II/III studies in patients with metastatic colorectal cancer

Study	Treatment	Phase	Regimen	Patients (n)	Overall response	Median PFS (mo)	Median OS (mo)
Cunnigham et al[22],	Refractory to irinotecan	2	Irinotecan+	218	22.90%	4.1	8.6
BOND study,			cetuximab
2004			vs
			cetuximab alone	211	10.80%	1.5	1.5
					P = 0.0074	P < 0.0001	P = 0.48
Van Cutsem et al[28],	First-line	3	FOLFIRI + cetuximab	105	36.20%	7.6	17.5
CRYSTAL trial,			vs
2009			placebo	87	40.20%	8.1	17.7
			(K-Ras mutant)		OR = 0.80	HR = 1.07	HR = 1.03
						P = 0.75
			FOLFIRI + cetuximab	172	59.30%	9.9	24.9
			vs
			placebo	176	43.20%	8.7	21.0
			(K-Ras wild-type)		OR = 1.91	HR = 0.68	HR = 0.84
					P = 0.004	P = 0.048
Bokemeyer et al[29,30],	First-line	2	FOLFOX + cetuximab	52	33%	8.6	NR
OPUS trial,			vs
2008			placebo	47	49%	5.5	NR
			(K-Ras mutant)		OR = 0.507	HR = 1.83
					P = 0.106	P = 0.0192
			FOLFOX + cetuximab	61	61%	7.7	NR
			vs
			placebo	73	37%	7.2	NR
			(K-Ras wild-type)		OR = 2.54	HR = 0.57
					P = 0.011	P = 0.016
Heinemann et al[31],	First line	3	FOLFIRI + cetuximab	297	62%	10.3	28.7
FIRE-3,			FOLFIRI + bevacizumab	295	57%	10.4	25.0
2013					OR = 1.249	HR = 1.04	HR = 0.77
					P = 0.18	P = 0.69	P = 0.017

PFS: Progression free survival; OS: Overall survival; NR: Not reported.